Latest news
Loading news…
Amytrx Therapeutics
ActiveOperating status — whether the company still runs independently. “Closed” usually means it was acquired, merged, or shut down.🔥 MediumHeat score — how much recent activity & attention the company has (web traffic, news, hiring).📈 Low growthGrowth score — momentum trend across web traffic, headcount and other growth signals. Nashville, Tennessee, United States Founded 2014 1-10 employees For Profit
Amytrx Therapeutics is a biopharmaceutical company that advances the next generation of new anti-inflammatory peptide therapies.
Total Funding
Available in Pro Last Funding
Available in Pro Acquisitions
0
Monthly Visits
Available in Pro Contacts
1
Patents
3
Company Details
Funding & Financials
Pro- Total funding
- Funding rounds
- Last funding
- Last funding type
- Last funding date
- Funding status
- Total equity funding
- Revenue range
IPO & Stock
- IPO status
- Private
Web Traffic
Pro- Monthly visits
- Global traffic rank
- 6-mo avg visits
- Visit duration (s)
- Pages / visit
- Bounce rate
- Rank change (mo)
Technology & IP
- Active technologies
- 4
- Patents granted
- 3
- Trademarks
- 0
- Top patent class
- Medical Or Veterinary Science; Hygiene
- IT spend
- $19K
Company Info
- Founded
- 2014
- Employees
- 1-10
- Operating status
- Active
- Company type
- For Profit
- Org types
- company
- Founders
- 1
- News articles
- 11
- HQ
- Nashville, Tennessee, United States
- Region
- Southern US
Signals & Scores
- Heat score
- Medium
- Growth score
- Low
- Trend (7d)
- -0.1
- Trend (30d)
- -0.4
- Trend (90d)
- -0.3
Key People at Amytrx Therapeutics
President, CEO, Co-Founder, and Director
1
professional contacts at Amytrx Therapeutics
Contact execs at Amytrx Therapeutics →Explore 200,000+ acquisitions — free
Filter the full database across sectors, companies, dates, and deal sizes. No signup, no paywall.
Recent News related to Amytrx Therapeutics
Loading news…
FAQs about Amytrx Therapeutics
People who checked this page also checked these
Browse the full Acquirezy directory.